In 2H, 2020, TAXIS will raise up to $2.5M in convertible preferred debt funding to further develop in the Clinic our lead gram-positive, QIDP-designated drug candidate, TXA709. We have raised$16M since inception from private investors including angels and prominent family offices.

TAXIS is engaged with multiple pharmaceutical companies with the intention to license or sell some or all of its technology platform in 2020/21.